Modulation of heme oxygenase-1 activity to enhance WT1-specific T-cell responses for immunotherapeutic approaches

      Wilms Tumor protein 1 (WT1) is expressed in a variety of solid tumors and is found in 80% of patients with acute myeloid leukemia. Previously it was shown that T cells recognizing WT1 are suitable for adoptive T-cell therapy. The efficiency of this therapeutic strategy is still limited due to the low frequency of WT1-specific T cells in peripheral blood of healthy donors.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect